Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DIABETIC CARDIOMYOPATHY. RESISTIN: A CONTROL OF A MYOCARDIAL HYPERTROPHY

https://doi.org/10.20996/1819-6446-2014-10-5-534-539

Full Text:

Abstract

Aim. To evaluate the association of serum resistin with morphological and functional indices of hypertrophic myocardium in patients with type 2 diabetes and chronic heart failure (CHF) with preserved left ventricular ejection fraction.

Material and methods. Patients (n=60; 12 men and 48 women) with type 2 diabetes and ischemic heart disease and CHF class II-III (NYHA) were included into the study. Clinical, laboratory and instrumental examinations, as well as determination of serum resistin were performed in all patients.

Results. Positive correlation was found between serum resistin level and left ventricle end-diastolic pressure (LV EDP; r=0.43; p=0.02) in patients with concentric left ventricular hypertrophy (LVH). Negative correlation was found between serum resistin level and LV EDP (r=-0.61; p=0.000) in patients with eccentric LVH. A number of supraventricular extrasystoles positively correlated with the serum resistin level (r=0.34; p=0.033) in patients with concentric LVH.

Conclusion. The role of "physiological" levels of resistin in the formation of cardiovascular indicators of the hypertrophic myocardium as well as possible prognostic significance of different levels of resistin for optimization of therapy are shown in patients with type 2 diabetes with CHF.

About the Authors

An. A. Aleksandrov
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


O. A. Shatskaya
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


S. S. Kuharenko
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


M. N. Yadrihinskaya
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


E. N. Abdalkina
Samara Medical Institute "Reaviz"
Russian Federation
Chapaevskaya ul. 227, Samara, 443001 Russia


E. N. Drozdova
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


M. V. Shestakova
Endocrinology Research Center
Russian Federation
Moskvorechye ul. 1, Moscow, 115478 Russia


References

1. Kim M., Oh JK., Sacata S. et al. Role of Resistin in Cardiac Contractility and Hypertention. J Moll Cell Cardiol 2008; 45(2): 270-80.

2. Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (FMPK/mTOR) and c-Jun N-terminal Kinase/Insulin Receptor Substrate 1( JNK/IRS1) Pathways. Biol Chem 2011; 286 (21): 18465-73.

3. Leiden J. The genetics of dilated cardiomyopathy: emerging clue to the puzzle. N Engl J Med 1997; 337:1080-1.

4. Towbin JA. Role of cytoskeletal proteins in cardiomyopathies. Current Opinions in Cell Biology 1998; 10: 131-9.

5. Bowles NE,Bowles KP, Towbin JA. The final common pathway hypothesis and inherited cardio-vascular disease: the role of citoskeletel proteins in dilated cardiomyopathy. Herz 2000; 25: 168-75.

6. Menzaghi C., Bacci S., Salvemini L. et al. Serum Resistin, Сardiovascular Disease and All-Cause Mortality in Patients with Type 2 DiabetesPloS ONE 2013; 896: e64729.

7. Boudina S., Abel ED. Diabetic Cardiomyopathy Revisited. Circulation 2007; 115: 3213-23.

8. Chemaly ER, Hadri L, Zhang S et al. Long-term in vivo Resistin Overexpression Induces Myocardial Dysfunction and Remodeling in Rats. J Moll Cell Cardiol 2011; 51(2):144-55.

9. Kim M. Resistin, a Novel Regulator of Cardiac function in Diabetic Cardiomyopathy. Ann Arbor, MI: ProQuest, UMI Dissertation Publishing; 2011.


For citation:


Aleksandrov A.A., Shatskaya O.A., Kuharenko S.S., Yadrihinskaya M.N., Abdalkina E.N., Drozdova E.N., Shestakova M.V. DIABETIC CARDIOMYOPATHY. RESISTIN: A CONTROL OF A MYOCARDIAL HYPERTROPHY. Rational Pharmacotherapy in Cardiology. 2014;10(5):534-539. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-534-539

Views: 334


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)